Compugen Ltd.

CGEN

$14.27

+296.05% (1 year change)

Avg closing price

Price range

Market Cap

$1.31 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

$-6.25 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-0.37

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-42.39x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-6.78 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

61

The number of full time employees.

Revenue & Earnings

Balance Sheet

Compugen Ltd.

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

News

Compugen Ltd. (NASDAQ:CGEN) Expected to Post Earnings of -$0.09 Per Share

Compugen Ltd. (NASDAQ:CGEN) Expected to Post Earnings of -$0.09 Per Share

Equities analysts predict that Compugen Ltd. (NASDAQ:CGEN) will announce earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued est...

The Olympia Report The Olympia Report, 4 days ago
Analysts Set Compugen Ltd. (NASDAQ:CGEN) Price Target at $19.56

Analysts Set Compugen Ltd. (NASDAQ:CGEN) Price Target at $19.56

Shares of Compugen Ltd. (NASDAQ:CGEN) have received a consensus rating of “Buy” from the eleven ratings firms that are presently covering the company, Marketbeat reports. Eleven analysts have rated...

Transcript Daily Transcript Daily, 5 days ago
Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors

Compugen Starts Dosing In Early-Stage Combination Study For Solid Tumors

Israel-based cancer immunotherapy firm Compugen announced that the first patient has been dosed in the Phase 1/2 study of COM701 with Bristol Myers … The post Compugen Starts Dosing In Early-Stage ...

Smarter Analyst Smarter Analyst, about 2 months ago